Quest PharmaTech Inc  

(Public, CVE:QPT)   Watch this stock  
Find more results for CVE:qpt
0.0450
0.0000 (0.00%)
Aug 25 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.04 - 0.05
52 week 0.03 - 0.11
Open 0.05
Vol / Avg. 76,000.00/25,053.00
Mkt cap 7.62M
P/E     -
Div/yield     -
EPS -0.04
Shares 150.42M
Beta 0.90
Inst. own     -

Key stats and ratios

Q2 (Apr '16) 2016
Net profit margin - -2055.46%
Operating margin - -857.91%
EBITD margin - -844.11%
Return on average assets -9.65% -84.61%
Return on average equity - -
CDP Score - -

Address

8123 Roper Rd NW
EDMONTON, AB T6E 6S4
Canada
+1-780-4481400 (Phone)
+1-780-4160324 (Fax)

Website links

Description

Quest PharmaTech Inc. is a Canada-based pharmaceutical company. The Company, through its subsidiary, OncoQuest Inc., is developing immunotherapies for cancer treatment. It operates through two segments: biopharmaceutical/pharmaceutical products and consumer/cosmetic products. OncoQuest's technology platform includes a panel of tumor antigen specific monoclonal immunoglobulins, including CA125, MUC1, PSA, and Her2/neu, and the application of combinatorial immunotherapy. OncoQuest's lead product, oregovomab, is undergoing a Phase IIb clinical trial involving approximately 80 ovarian cancer patients in Italy and the United States. OncoQuest's pipeline of product candidates consists of four other monoclonal antibodies targeting certain tumor antigens that are presented in a range of cancers, including such cancers as breast, lung, pancreas, stomach and prostate. It also markets consumer health products around the world, including Bellus Skin serum, an anti-wrinkle skin care product.

Officers and directors

Lorne Meikle Independent Chairman of the Board
Ragupathy Madiyalakan Ph.D. Chief Executive Officer, Director
Pierre Vermette Chief Financial Officer
Thomas Woo Vice President - Product Development
Shawn Shuguang Lu Director
Ian McConnan Independent Director
Eric Shi MD, PhD Independent Director